A new experimental nasal spray that uses a dry powder instead of a needle could offer another option for treating severe allergic reactions. According to research presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, two doses of an investigational nasal powder called FMXIN002 (also known as NS002) entered the bloodstream more quickly and produced more sustained epinephrine exposure than two doses delivered by a traditional auto-injector. Because an estimated 8% to 28% of patients treated for anaphylaxis—a potentially life-threatening allergic reaction—require a second dose of epinephrine, demonstrating that repeat doses can be absorbed reliably is an important milestone for any needle-free alternative.
Developed by Nasus Pharma, FMXIN002 is administered through a single-use nasal device and builds upon earlier studies that compared single doses of the powder with standard 0.3-mg auto-injectors such as the EpiPen. Unlike liquid nasal sprays that can drip out of the nose or down the throat, the powder formulation is designed to adhere evenly to the nasal passages. Dr Michael S Blaiss, a clinical professor at the Medical College of Georgia at Augusta University, emphasized the benefit of this design in an interview with HCPLive: “What’s important here versus a liquid epinephrine formulation is with this particular powder, you can get uniform nasal surface adhesion and minimal runoff or drip.”
Getting epinephrine into the bloodstream quickly is essential during an allergic emergency, as anaphylaxis can rapidly restrict breathing and cause a dangerous drop in blood pressure. As Dr Blaiss explained, “It’s important you get high and fast absorption of epinephrine throughout your body to counteract the manifestations of anaphylaxis.” Researchers designed the latest study to determine whether the nasal powder could maintain rapid absorption when administered a second time, including under conditions that might interfere with delivery through the nose.
The trial enrolled 50 adults with allergic rhinitis, commonly known as nasal allergies. Participants received two 4-mg doses of FMXIN002 spaced 10 minutes apart, either in the same nostril or opposite nostrils. Researchers measured epinephrine levels in their blood for up to four hours and compared the findings with those from two doses of a standard 0.3-mg auto-injector. The different amounts reflect the distinct delivery methods and cannot be directly compared to determine how much medication reaches the bloodstream. Importantly, the nasal powder was tested both under normal conditions and after researchers deliberately triggered nasal congestion using an allergen challenge. Because nasal congestion can accompany anaphylaxis, confirming that the medication can still be absorbed under these conditions is particularly important. The study evaluated drug absorption rather than treatment effectiveness during actual anaphylactic emergencies.
The results showed that the nasal powder reached a key blood concentration threshold significantly faster than the traditional injection while producing comparable or higher peak epinephrine levels. Within just two and a half minutes, 60% to 82% of participants receiving FMXIN002 reached a blood concentration of at least 100 picograms per milliliter, compared with only 16.7% of those receiving the auto-injector. Across the dosing conditions, the nasal powder consistently reached this target concentration faster, a statistically significant finding. However, reaching a particular blood concentration does not, by itself, establish that the medication will reverse anaphylaxis more quickly or effectively.
Dr Blaiss also noted that epinephrine levels from the nasal powder exceeded those from the auto-injector within the first five minutes and reached a higher peak approximately 20 minutes after dosing. The study also found that administering both doses into the same nostril or into opposite nostrils produced similarly favorable absorption results. “It didn’t matter whether it was given in the same nostril or contralateral nostril,” Dr Blaiss explained. These findings suggest that patients may have flexibility in how they administer a second dose during an emergency. The repeat-dose evaluation also addresses an important FDA requirement to demonstrate that additional doses can be administered safely while achieving appropriate drug exposure and physiological responses.
By demonstrating rapid and consistent epinephrine absorption following repeat doses, even under conditions of nasal congestion, the findings represent another encouraging step toward a potential needle-free treatment for anaphylaxis. However, additional research is needed to establish how well FMXIN002 performs during actual allergic emergencies. For people who carry epinephrine auto-injectors, particularly those who hesitate to use needles, another effective nasal alternative could eventually make emergency treatment easier and more accessible.
